/PRNewswire/ Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that the U.S. Food and Drug Administration.
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2- Dosing of first
/PRNewswire/ Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation.